TeleflexTFX
Recorded

Teleflex 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 1 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, ladies and gentlemen, and welcome to the Teleflex Third Quarter 2026 Earnings Conference Call. At this time, all participants have been placed in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. Please note that this conference call is being recorded and will be available on the company's website for replay shortly. I will turn the call over to Mr. Lawrence Keusch, Vice President of Investor Relations and Strategy Development.

Lawrence KeuschVP of Investor Relations and Strategy Development

Good morning, everyone, and welcome to the Teleflex Incorporated Third Quarter 2026 Earnings Conference Call. The press release and slides to accompany this call are available on our website at teleflex.com. As a reminder, a replay will be available on our website. Those wishing to access the replay can refer to our press release from this morning for details. Joining me on today's call are Jason Weidman, President and Chief Executive Officer, and John Deren, Executive Vice President and Chief Financial Officer. Jason and John will provide prepared remarks, then we will open the call to Q&A. Before we begin, I would like to remind you that some of the matters discussed in the conference call will contain forward-looking statements regarding future events, as outlined in the slides posted to the Investor Relations section of the Teleflex website.

Lawrence KeuschVP of Investor Relations and Strategy Development

We wish to caution you that such statements are, in fact, forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ materially include, but are not limited to, factors referenced in our press release today, as well as our filings with the SEC, including our Form 10-K, which can be accessed on our website. Now, I will turn the call over to Jason for his remarks.

Jason WeidmanPresident and CEO

Thank you, Larry, and good morning, everyone. Let me start this morning with the highlights of the quarter. Teleflex delivered strong third quarter performance, with pro forma adjusted constant currency revenue growth of 3%, and adjusted operating margin of 25%. Even excluding the benefit of the refund for IEEPA tariffs paid in 2026, adjusted margins saw modest expansion, and earnings per share grew. Vascular and Surgical continued to deliver solid growth, while Interventional returned to positive growth, improving on its second quarter performance. We also continued our return of capital to shareholders with $350 million in additional share buybacks, $100 million more than previously announced, between the beginning of Q3 and today. As John will discuss, we are increasing our full-year adjusted EPS guidance to reflect our third quarter progress and our outlook for the remainder of the year.

Jason WeidmanPresident and CEO

I've now been in the CEO role here at Teleflex for about five months. I've continued my extensive review of the organization, spent significant time visiting sites and customers across the globe, and ensured focus on our critical executional priorities. On our last call, I said I would have more to say about my perspective on the business and our future direction by this call. While I still consider it early in my tenure, I'd like to share some insights, particularly on our growth strategy, and then turn to our priorities and expectations for the future. As previously discussed, Teleflex is in the midst of a massive transformation, and I want to thank our employees for the tremendous effort, dedication, and extra work they have put in to continue driving the transformation forward.

Jason WeidmanPresident and CEO

Now that I have a firsthand view of what is really required, I can tell you that I'm very proud of our team. While we have always said that 2026 would be a transition year, we have made significant progress and reached tangible milestones, including combining the Vascular Intervention and Teleflex Interventional Access teams, closing the OEM divestiture, and returning significant capital to shareholders. We expect that these efforts will enhance our financial profile in 2027 with higher adjusted margins, lower interest expense, a lower share count, and a meaningful step-up in adjusted EPS. While much progress has been made, we have more to do to generate the long-term growth that I am confident Teleflex can deliver. My top priorities are threefold.

Jason WeidmanPresident and CEO

First, we need to strengthen our foundation by delivering our transformation, including closing the Acute Care and Interventional Urology divestiture and fully completing the integration of our Interventional business to position it for sustainable growth. Second, we need to accelerate our organizational effectiveness by fully implementing a global business unit structure and simplifying our operating model. Third, we need to elevate our growth profile by advancing innovation and key growth drivers within a balanced capital allocation framework. Together, these priorities are about building a more focused, agile, and growth-oriented Teleflex, a company that is closer to its customers, faster in how it operates, and better positioned to deliver meaningful innovation and sustainable growth.

Jason WeidmanPresident and CEO

Beginning with the first priority, which is clearly the most important in the near term, we need to fully execute on the foundational elements of our transformation to deliver a newly focused Teleflex that is built to grow. Operationally, our immediate focus is successfully completing the Interventional integration. While it has taken longer than we originally planned, we made notable progress in the third quarter on the three transition dynamics I outlined in August, and I'll walk through some of the details when I cover Interventional's results a bit later. Our go-forward success with Interventional comes down to focus and execution. I believe strongly that we now have the right strategy, great products, and people to position Interventional for improving growth over the coming years.

Jason WeidmanPresident and CEO

We recently strengthened the leadership of this business with the addition of Jason Fontana, who joined as President and General Manager of Interventional, effective September 14th. He brings more than 20 years of leadership experience across interventional markets, spanning global P&L responsibility, commercial strategy, market development, innovation, and business growth. I have known and worked with Jason for about two decades, and I am very confident in his ability to lead this business through a successful integration and beyond. Also critical to delivering on our transformation is completing the Acute Care and Interventional Urology divestiture. I want to be clear, we are confident this transaction will be completed. As previously disclosed, the FTC issued a Second Request in March. Its review is focused on a small area of product overlap with the buyer's existing portfolio, which is a defined and manageable issue.

Jason WeidmanPresident and CEO

As a reminder, this is a buyer-led process, so we are working closely with Intersurgical to support. While we continue to work to close the transaction by year-end, the precise timing remains subject to the regulatory process and could extend into 2027. That said, I will reiterate that we remain confident in completing the overall transaction and are encouraged by the progress being made. For us to truly capitalize on the leaner, more focused Teleflex that we are building, we are going to need to change how we operate. This leads to my second priority of accelerating our organizational effectiveness. Historically, Teleflex was organized geographically, which often led to different approaches in different parts of the world. Over time, it created a complex matrix in which accountability was spread across too many people and objectives were not always aligned.

Jason WeidmanPresident and CEO

Candidly, it also created a heavy process burden that, at times, pulled our focus away from the customer and slowed us down. To remove those barriers to execution, we are in the midst of implementing a global business unit structure and simplifying our operating model to drive sharper customer focus, clear accountability, and faster decisions. This quarter marks an important milestone for us in this regard. We now manage and report as three global business units: Vascular, Interventional, and Surgical. The BUs now have clear line of sight across the globe and the mandate to optimally deploy their resources to maximize growth. Each business will own its strategy, resources, and results. Our goal is straightforward: to put customers at the center of our decisions, empower our global businesses to lead, and ensure our corporate functions help them move faster and execute more effectively.

Jason WeidmanPresident and CEO

We have also simultaneously embarked on a number of initiatives to reduce process complexity and simplify our operating mechanisms. Altogether, this is another big transition for our company, for our employees, and for how we operate. But I will tell you that our employees are really energized. There is a strong belief that we can positively change so that it is easier for our teams to get things done and better serve our customers. My third priority is to elevate our growth profile by advancing innovation in our key growth drivers within a balanced capital allocation framework. Beyond our previously committed redeployment of divestiture proceeds, which encompasses $1 billion of share repurchases and $800 million of debt reduction, our approach to capital deployment is to invest in R&D and CapEx to fund organic growth, maintain a strong balance sheet, and use excess capital for share buybacks or eventually M&A.

Jason WeidmanPresident and CEO

From an organic growth standpoint, historically, the vast majority of our R&D went to sustaining products and iterations, and planning cycles tended to be shorter term. We are changing that. We have taken R&D investment from historical levels of about 5%-6% of revenue to close to 8%, and we are directing more of that spend towards substantive innovation. Freesolve, our resorbable magnesium scaffold, is one example. As we reported this summer, we completed the enrollment in the BIOMAG-II trial ahead of schedule, with a data readout expected in late 2027, and our U.S. pivotal trial, BIOMAG-III, is underway. More recently, we completed the patient enrollment in the European BIOMAG-LL clinical study, which is assessing the clinical efficacy and safety of extended length 35 millimeter and 40 millimeter Freesolve resorbable scaffolds in long lesion lengths, which remain among the most challenging lesion subsets in PCI.

Jason WeidmanPresident and CEO

Finally, we were excited to announce two weeks ago that Freesolve received breakthrough device designation for PCI from the FDA, which signals the novelty of our approach and provides us closer interaction with the agency as we move the program forward. EZPLAZ is another substantive organic innovation example where we see meaningful future potential. Its approval in late July was a landmark for Teleflex, and on our last call, several of you asked how we think about the opportunity. When we spoke in August, I said we had more to learn, and over the past quarter, we have learned a lot. EZPLAZ is the first and only FDA-licensed freeze-dried plasma, and interest from customers has been high. It addresses a significant unmet need. Today, the standard of care is frozen plasma, which has to be stored frozen and thawed before use.

Jason WeidmanPresident and CEO

That limits where plasma can be deployed and how quickly it can reach a patient. EZPLAZ is stored at room temperature and is ready to reconstitute in minutes. That makes plasma available on the battlefield, in air and road ambulances, and in trauma centers that want immediate access to plasma in every situation without waiting for it to thaw. Our flexible bag is also a meaningful differentiator against the glass container formats we expect from future freeze-dried competitors. As the only licensed product with these attributes, we have a first-mover advantage, and we believe EZPLAZ will set the standard against which any future entrant is measured. On market size, I told you last quarter that I wanted to thoroughly assess before putting a number on it.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day